Mineralys Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Mineralys Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q3 2024.
  • Mineralys Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$56.3M, a 148% decline year-over-year.
  • Mineralys Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$153M, a 171% decline year-over-year.
  • Mineralys Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$71.9M, a 141% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$153M -$56.3M -$33.6M -148% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$120M -$41M -$28.9M -238% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$90.8M -$31.5M -$18.9M -150% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$71.9M -$24.4M -$15.3M -169% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$56.6M -$22.8M -$16.1M -241% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$40.5M -$12.1M -$5.66M -87.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$34.8M -$12.6M -$5.04M -66.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$29.8M -$9.07M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$6.68M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$6.48M Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$7.57M Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.